Cross Optum programs turn evidence into action
In this fragmented healthcare landscape, life sciences organizations are faced with the challenge of how to connect the pieces. They’re asking how to:
- Improve efficiency of timely diagnosis
- Test new processes that could improve clinical decision-making and therapy adherence
- Discover effective ways to improve guidelines for directed therapy and evidence-based medicine
- Understand patient and provider behavior in the real world
- Educate patients on therapy options and the benefits of staying on track with their treatment
Small changes can make a big difference. The Cross Optum team works with life sciences companies and the larger UnitedHealth Group® enterprise to identify unmet needs, design and pilot engagement programs, and evaluate outcomes.
Connecting parts of the healthcare ecosystem
Our team uses implementation science to generate evidence that serves as a catalyst to improve the future of health care.
Key benefits
Clinical programs and process improvements to existing interactions help foster adoption across stakeholders. We focus on the following:
Disease awareness and prevention
Identify at-risk individuals and help resolve healthcare gaps.
Guideline-directed care
Improve quality and consistency of patient care across the healthcare ecosystem.
Treatment, intensification and adherence
Collaborate to increase adherence and improve outcomes.
Case study
Lowering cardiovascular disease risk
An innovative program involving patient awareness and provider outreach helps improve patient use of lipid-lowering therapies.
Build evidence to reach and treat the right populations
Optum designed a program to introduce an assessment tool and prepare clinicians with training and a guide to aid diagnosis and treatment.
Related healthcare insights
Article
An innovative program involving patient awareness and provider outreach improves patient use of lipid-lowering therapies.
Article
See how the FDA and Optum use real-world evidence to monitor the safety and effectiveness of COVID-19 vaccines in our youngest populations.
Guide
As a key FDA collaborator, Optum Epidemiology generates reproducible results that inform regulatory decisions for COVID-19 vaccines.
Olivia Banyon, MPH
Vice President
Tina Kelley
Senior Director
Aimee Coughlin, MBA
Senior Consultant
Katherine Ferro, MHSA, MBA
Senior Consultant
Nick Payne, MBA
Senior Consultant
Kizzy Steward-Judie, PharmD, MBA
Clinical Lead Consultant
Maggie Reyes-Leczinski
Senior Consultant
Sheriden Beard, MPH
Senior Research Analyst